The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

June 21, 2024

Patients with leptomeningeal metastasis from HER2-positive breast cancer experienced clinical benefit with tucatinib plus trastuzumab and capecitabine.

June 20, 2024

Shubham Pant, MD, MBBS, discusses the utility of zanidatamab in patients with previously treated HER2+ biliary tract cancer.

June 17, 2024

Frontline treatment with acalabrutinib and bendamustine/rituximab (BR) improved PFS over BR alone in older patients with mantle cell lymphoma.

June 12, 2024

Sattva S. Neelapu, MD, discusses processes that have been adopted to streamline the delivery of CAR T-cell therapy to patients with lymphoma.

June 11, 2024

Sattva S. Neelapu, MD, discusses key clinical trial data that support the use of CAR T-cell therapy in standard practice for patients with lymphoma.

June 03, 2024

Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.

June 02, 2024

Zanidatamab continued to show confirmed responses, disease control, and prolonged overall survival in pretreated HER2+ biliary tract cancer.

June 02, 2024

Consolidation treatment with durvalumab after concurrent chemoradiation led to a survival benefit vs placebo in limited-stage small cell lung cancer.

May 30, 2024

Daniel M. Halperin, MD, discusses the FDA approval of lutetium Lu 177 dotatate for pediatric patients with SSTR-positive GEP-NETs.

May 30, 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

May 30, 2024

Timothy Yap, MBBS, PhD, FRCP, discusses next steps for investigating saruparib in advanced solid tumors with genetic mutations, including prostate cancer.

May 28, 2024

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for investigating saruparib in advanced solid tumors, such as prostate cancer with genetic mutations.

May 23, 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

May 21, 2024

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

May 15, 2024

Debu Tripathy, MD, discusses the current state of HER2-positive breast cancer treatment.

May 13, 2024

Debu Tripathy, MD, discusses real-world strategies for CDK4/6 inhibitor use and the importance of HER2 testing in HER2-positive metastatic breast cancer.

May 10, 2024

Parul N Barry, MD, discusses the integration of partial breast irradiation therapy into the treatment of patients with breast cancer.

May 10, 2024

Ramez Kouzy, MD, discusses efforts to improve knowledge of the use of AI in radiation oncology through the creation of an online repository.

May 09, 2024

James Ignatz-Hoover, MD, PhD, discusses the current arsenal of FDA-approved bispecific antibodies in multiple myeloma.

May 09, 2024

Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.